Article
Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype.
Diabetes - 1 Oct 2008
Asleh Rabea, Blum Shany, Kalet-Litman Shiri, Alshiek Jonia, Miller-Lotan Rachel, Asaf Roy, Rock Wasseem, Aviram Michael, Milman Uzi, Shapira Chen, Abassi Zaid, Levy Andrew P
Abstract excerpt
OBJECTIVE: Pharmacogenomics is a key component of personalized medicine. The Israel Cardiovascular Events Reduction with Vitamin E Study, a prospective placebo-controlled study, recently demonstrated that vitamin E could dramatically reduce CVD in individuals with diabetes and the haptoglobin (Hp) 2-2 genotype (40% of diabetic individuals). However, because of the large number of clinical trials that failed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
